Tumor necrosis factor inhibitors for the treatment of asthma

Current Allergy and Asthma Reports

Volumn 7, Issue 2, 2007, Pages 151-156

  Kim, Jiyoun ^a   Remick, Daniel G ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AUTACOID; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ETANERCEPT; GAMMA INTERFERON; IMMUNOGLOBULIN E; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 12; INTERLEUKIN 5; MARIMASTAT; OMALIZUMAB; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; VASCULAR CELL ADHESION MOLECULE 1;

AIRWAY OBSTRUCTION; ASTHMA; BRONCHUS HYPERREACTIVITY; CELL ACTIVATION; CLINICAL TRIAL; CROHN DISEASE; DEMYELINATING DISEASE; DISEASE MODEL; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IMMUNOREGULATION; MULTIPLE SCLEROSIS; PROTEIN INDUCTION; PROTEIN SYNTHESIS; PSORIASIS; RESPIRATORY TRACT INFLAMMATION; REVIEW; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME; TUBERCULOSIS;

ANIMALS; ANTI-ASTHMATIC AGENTS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ASTHMA; BIOLOGICAL RESPONSE MODIFIERS; BRONCHIAL HYPERREACTIVITY; BRONCHOALVEOLAR LAVAGE FLUID; HUMANS; IMMUNOGLOBULIN G; INFLAMMATION; MICE; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME; TUMOR NECROSIS FACTORS;

EID: 34248369746     PISSN: 15297322     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11882-007-0013-3     Document Type: Review

References (61)

1. Braman SS: The global burden of asthma [review]. Chest 2006, 130(1 suppl):4S-12.
2. World Health Organization: Facts about asthma. In WHO Fact Sheet 2006. Available at: http://www.who.int/media-centre/factsheets/fs307/ en/index.html. Accessed September 20, 2006.
3. Masoli M, Fabian D, Holt S, et al.: The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004, 59:469-478.
4. Beasley R: The burden of asthma with specific reference to the United States. J Allergy Clin Immunol 2002, 109: S482-S489.
5. Wagelie-Steffen AL, Kavanaugh AF, Wasserman SI: Biologic therapies for the treatment of asthma. Clin Chest Med 2006, 27:133-147.
6. Erzurum SC: Inhibition of tumor necrosis factor alpha for refractory asthma. N Engl J Med 2006, 354:754-758.
7. Russo C, Polosa R: TNF-alpha as a promising therapeutic target in chronic asthma: a lesson from rheumatoid arthritis. Clin Sci (Lond) 2005, 109:135-142.
8. Buhl R: Anti-IgE antibodies for the treatment of asthma. Curr Opin Pulm Med 2005, 11:27-34.
9. Poole JA, Matangkasombut P, Rosenwasser LJ: Targeting the IgE molecule in allergic and asthmatic diseases: review of the IgE molecule and clinical efficacy. J Allergy Clin Immunol 2005, 115:S376-S385.
10. Barnes PJ: Cytokine modulators as novel therapies for asthma. Annu Rev Pharmacol Toxicol 2002, 42:81-98.
11. Howarth PH, Babu KS, Arshad HS, et al.: Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax 2005, 60:1012-1018.
12. Kim J, McKinley L, Natarajan S, et al.: Anti-tumor necrosis factor-alpha antibody treatment reduces pulmonary inflammation and methacholine hyper-responsiveness in a murine asthma model induced by house dust. Clin Exp Allergy 2006, 36:122-132.
13. Hanauer SB, Sandborn WJ, Rutgeerts P, et al.: Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006, 130:323-333.
14. Scott DL, Kingsley GH: Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med 2006, 355:704-712.
15. Carswell EA, Old LJ, Kassel RL, et al.: An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A 1975, 72:3666-3670.
16. Beutler B, Mahoney J, Le Trang N, et al.: Purification of cachectin, a lipoprotein lipase-suppressing hormone secreted by endotoxin-induced RAW 264.7 cells. J Exp Med 1985, 161:984-995.
17. Wollenberg GK, DeForge LE, Bolgos G, et al.: Differential expression of tumor necrosis factor and interleukin-6 by peritoneal macrophages in vivo and in culture. Am J Pathol 1993, 143:1121-1130.
18. Call DR, Nemzek JA, Ebong SJ, et al.: Differential local and systemic regulation of the murine chemokines KC and MIP2. Shock 2001, 15:278-284.
19. DeForge LE, Remick DG: Kinetics of TNF, IL-6, and IL-8 gene expression in LPS-stimulated human whole blood. Biochem Biophys Res Commun 1991, 174:18-24.
20. Caput D, Beutler B, Hartog K, et al.: Identification of a common nucleotide sequence in the 3′-untranslated region of mRNA molecules specifying inflammatory mediators. Proc Natl Acad Sci U S A 1986, 83:1670-1674.
21. Hsi ED, Remick DG: Rapid determination of cell-associated tumor necrosis factor production by flow cytometry. Lab Invest 1993, 68:740-745.
22. Black RA: Tumor necrosis factor-alpha converting enzyme. Int J Biochem Cell Biol 2002, 34:1-5.
23. Haack M, Pollmacher T, Mullington JM: Diurnal and sleep-wake dependent variations of soluble TNF- and IL-2 receptors in healthy volunteers. Brain Behav Immun 2004, 18:361-367.
24. Leeuwenberg JF, Dentener MA, Buurman WA: Lipopolysaccharide LPS-mediated soluble TNF receptor release and TNF receptor expression by monocytes. Role of CD14, LPS binding protein, and bactericidal/ permeability-increasing protein. J Immunol 1994, 152:5070-5076.
25. Truyens C, Torrico F, Lucas R, et al.: The endogenous balance of soluble tumor necrosis factor receptors and tumor necrosis factor modulates cachexia and mortality in mice acutely infected with Trypanosoma cruzi. Infect Immun 1999, 67:5579-5586.
26. Fisher CJ, Jr., Agosti JM, Opal SM, et al.: Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 1996, 334:1697-1702.
27. Waage A, Halstensen A, Espevik T: Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1987, 1:355-357.
28. Holgate ST, Holloway J, Wilson S, et al.: Understanding the pathophysiology of severe asthma to generate new therapeutic opportunities. J Allergy Clin Immunol 2006, 117:496-506; quiz 507.
29. Shah A, Church MK, Holgate ST: Tumour necrosis factor alpha: a potential mediator of asthma. Clin Exp Allergy 1995, 25:1038-1044.
30. Thomas PS: Tumour necrosis factor-alpha: the role of this multifunctional cytokine in asthma. Immunol Cell Biol 2001, 79:132-140.
31. Babu KS, Davies DE, Holgate ST: Role of tumor necrosis factor alpha in asthma. Immunol Allergy Clin North Am 2004, 24:583-597.
32. Coward WR, Okayama Y, Sagara H, et al.: NF-kappa B and TNF-alpha: a positive autocrine loop in human lung mast cells? J Immunol 2002, 169:5287-5293.
33. Berry MA, Hargadon B, Shelley M, et al.: Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med 2006, 354:697-708.
34. Gordon JR, Galli SJ: Release of both preformed and newly synthesized tumor necrosis factor alpha (TNF-alpha)/cachectin by mouse mast cells stimulated via the Fc epsilon RI. A mechanism for the sustained action of mast cell-derived TNF-alpha during IgE-dependent biological responses. J Exp Med 1991, 174:103-107.
35. Thomas PS, Yates DH, Barnes PJ: Tumor necrosis factor-alpha increases airway responsiveness and sputum neutrophilia in normal human subjects. Am J Respir Crit Care Med 1995, 152:76-80.
36. Lukacs NW, Strieter RM, Chensue SW, et al.: TNF-alpha mediates recruitment of neutrophils and eosinophils during airway inflammation. J Immunol 1995, 154:5411-5417.
37. Casale TB, Costa JJ, Galli SJ: TNF alpha is important in human lung allergic reactions. Am J Respir Cell Mol Biol 1996, 15:35-44.
38. Amrani Y, Chen H, Panettieri RA Jr: Activation of tumor necrosis factor receptor 1 in airway smooth muscle: a potential pathway that modulates bronchial hyper-responsiveness in asthma? Respir Res 2000, 1:49-53.
39. Tosi MF, Stark JM, Smith CW, et al.: Induction of ICAM-1 expression on human airway epithelial cells by inflammatory cytokines: effects on neutrophil-epithelial cell adhesion. Am J Respir Cell Mol Biol 1992, 7:214-221.
40. Thornhill MH, Wellicome SM, Mahiouz DL, et al.: Tumor necrosis factor combines with IL-4 or IFN-gamma to selectively enhance endothelial cell adhesiveness for T cells. The contribution of vascular cell adhesion molecule-1-dependent and -independent binding mechanisms. J Immunol 1991, 146:592-598.
41. Busse PJ, Zhang TF, Srivastava K, et al.: Chronic exposure to TNF-alpha increases airway mucus gene expression in vivo. J Allergy Clin Immunol 2005, 116:1256-1263.
42. Levine SJ, Larivee P, Logun C, et al.: Tumor necrosis factor-alpha induces mucin hypersecretion and MUC-2 gene expression by human airway epithelial cells. Am J Respir Cell Mol Biol 1995, 12:196-204.
43. Lora JM, Zhang DM, Liao SM, et al.: Tumor necrosis factor-alpha triggers mucus production in airway epithelium through an IkappaB kinase beta-dependent mechanism. J Biol Chem 2005, 280:36510-36517.
44. Choi IW, Sun K, Kim YS, et al.: TNF-alpha induces the late-phase airway hyperresponsiveness and airway inflammation through cytosolic phospholipase A(2) activation. J Allergy Clin Immunol 2005, 116:537-543.
45. Kips JC, Tavernier J, Pauwels RA: Tumor necrosis factor causes bronchial hyperresponsiveness in rats. Am Rev Respir Dis 1992, 145:332-336.
46. Holgate ST: Cytokine and anti-cytokine therapy for the treatment of asthma and allergic disease. Cytokine 2004, 28:152-157.
47. Toussirot E, Wendling D: The use of TNF-alpha blocking agents in rheumatoid arthritis: an overview. Expert Opin Pharmacother 2004, 5:581-594.
48. Bruce C, Thomas PS: The effect of marimastat, a metalloprotease inhibitor, on allergen-induced asthmatic hyper-reactivity. Toxicol Appl Pharmacol 2005, 205:126-132.
49. van Deventer SJ: A place for TACE [comment]. Gut 2002, 51:5-6.
50. Rudmann DG, Moore MW, Tepper JS, et al.: Modulation of allergic inflammation in mice deficient in TNF receptors. Am J Physiol Lung Cell Mol Physiol 2000, 279:L1047-L1057.
51. Zuany-Amorim C, Manlius C, Dalum I, et al.: Induction of TNF-alpha autoantibody production by AutoVac TNF106: a novel therapeutic approach for the treatment of allergic diseases. Int Arch Allergy Immunol 2004, 133:154-163.
52. Bruce CT, Thomas PS: TNF-alpha as a target for anti-asthma therapy [letter]. Clin Sci (Lond) 2006, 110:265.
53. Campbell IK, Roberts LJ, Wicks IP: Molecular targets in immune-mediated diseases: the case of turnout necrosis factor and rheumatoid arthritis. Immunol Cell Biol 2003, 81:354-366.
54. Oliveri C, Polosa R: Etanercept in chronic severe asthma [comment]. Thorax 2006, 61:640; author reply 640.
55. Fleischmann RM, Iqbal I, Stern RL: Considerations with the use of biological therapy in the treatment of rheumatoid arthritis. Expert Opin Drug Saf 2004, 3:391-403.
56. Fleischmann R, Iqbal I, Nandeshwar P, et al.: Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept. Drug Saf 2002, 25:173-197.
57. Gomez-Reino JJ, Carmona L, Valverde VR, et al.: Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003, 48:2122-2127.
58. Wallis RS, Broder MS, Wong JY, et al.: Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004, 38:1261-1265.
59. Mohan N, Edwards ET, Cupps TR, et al.: Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001, 44:2862-2869.
60. Robinson WH, Genovese MC, Moreland LW: Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? Arthritis Rheum 2001, 44:1977-1983.
61. Davydov L: Omalizumab (Xolair) for treatment of asthma. Am Fam Physician 2005, 71:341-342.